Male osteoporosis: A review
Herrera A, Lobo-Escolar A, Mateo J, Gil J, Ibarz E, Gracia L. World J Orthop. 2012 Dec 18;3(12):223-34. doi: 10.5312/wjo.v3.i12.223.

Source

Antonio Herrera, Antonio Lobo-Escolar, Jesús Mateo, Jorge Gil, Department of Orthopedic and Trauma Surgery, Miguel Servet University Hospital, 50009 Zaragoza, Spain.

Abstract

Osteoporosis in men is a heterogeneous disease that has received little attention. However, one third of worldwide hip fractures occur in the male population. This problem is more prevalent in people over 70 years of age. The etiology can be idiopathic or secondary to hypogonadism, vitamin D deficiency and inadequate calcium intake, hormonal treatments for prostate cancer, use of toxic and every disease or drug use that alters bone metabolism.Risk factors such as a previous history of fragility fracture should be assessed for the diagnosis. However, risk factors in men are very heterogeneous. There are significant differences in the pharmacological treatment of osteoporosis between men and women fundamentally due to the level of evidence in published trials supporting each treatment. New treatments will offer new therapeutic prospects. The goal of this work is a revision of the present status knowledge about male osteoporosis.